Helicobacter heilmannii sensu lato :An overview of the infection in humans

Helicobacter heilmannii sensu lato(H.heilmannii s.l.)is a group of gastric non-Helicobacter pylori Helicobacter species that are morphologically indistinguishable from each other.H.heilmannii s.l.infect the stomach of several animals and may have zoonotic potential.Although the prevalence of these infections in humans is low,they are associated with gastric pathology,including mucosa-associated lymphoid tissue lymphoma,making them a significant health issue.Here,the taxonomy,epidemiology,microbiology,diagnosis,and treatment of these infections will be reviewed.The gastric pathology associated with H.heilmannii s.l.infections in humans will also be addressed.Finally,the features of the complete bacterial genomes available and studies on species-specific pathogenesis will be reviewed.The understanding of the mechanisms that underlie gastric disease development mediated by the different bacterial species that constitute H.heilmannii s.l.is essential for developing strategies for prevention and treatment of these infections.

中药“养肺方”联合氩氦刀冷冻治疗老年晚期非小细胞肺癌的临床研究

目的:研究中药"养肺方"联合氩氦刀冷冻治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效。方法:收集自2012年6月至2015年6月期间老年晚期NSCLC并接受氩氦刀冷冻治疗患者共130例,分为中西医结合组65例("养肺方"+最佳对症治疗)和西医治疗组65例(最佳对症支持),评价其近期疗效(影像学评价、生活质量评价)和生存获益[总生存期(OS)、术后生存期和无进展生存期(PFS)]。结果:1影像学评价:两组氩氦刀治疗的手术部位、病灶大小及手术次数、术中CT影像监测评价及有效率比较,差异均无统计学意义,两组接受氩氦刀手术情况具有可比性;2生活质量(QOL)比较:中西医结合组术后3个月QOL评分为(47.85±2.78),与西医治疗组同期(46.15±3.43)比较明显提高(P<0.01);3远期疗效:中西医结合组术后生存期为14个月,OS为23个月;西医治疗组术后生存期为12个月,OS为21个月,中西医结合组术后生存期和OS均比西医治疗组稍长,但差异无统计学意义;中西医结合组PFS为7个月,比西医治疗组(5个月)长(P<0.05)。结论:养肺方联合氩氦刀冷冻治疗老年晚期NSCLC近期能提高患者生活质量,远期在延长PFS方面表现出优势,是值得进一步研究和推广的治疗模式。